At any point in fetal life, approximately 30% of the fetus’ blood volume is circulating through the placenta where all respiratory and many metabolic functions occur. At birth, allowing this blood to be redistributed to the infant provides up to 50% more iron-rich red blood cells in the circulation [1]. These red blood cells contribute to higher iron stores in infancy [2]. Placental transfusion which facilitates this blood transfer is accomplished in one of three ways: delayed cord clamping (DCC); milking the umbilical cord (UCM) before separating it from the placenta; or clamping and cutting the umbilical cord and milking after cutting (C-UCM). Most studies contrast these methods to immediate cord clamping (ICC), the dominant world-wide practice. In term infants, placental transfusion can result in increased iron stores during the first 6 months of life [2].

There is no meta-analysis for late preterm infants with placental transfusion. Only two other studies specifically address this age group. The first examined infants between 34-36 weeks (n=41) and compared a 3-minute delay versus ICC [5]. They found higher hemoglobin levels at 1 day and 10 weeks without any difference in jaundice [5]. Ranjit, et al. [6] randomized 94 infants between 30 and 36 weeks to either DCC (at least 2 minutes) or ICC. They found higher hematocrit and ferritin levels at 6 weeks of age. The DCC group had longer duration of phototherapy but no difference in the incidence of significant jaundice.

Comparisons across studies of late preterm infants are difficult because age groupings are inconsistent. Many available studies draw conclusions from samples containing both early preterm and late preterm infants. Yet, health differences between infants at 32 weeks versus 36 weeks are striking. Infants at 32 to 34 weeks have double the mortality of those at 35 to 36 weeks (18.5 versus 6.9/1000, US statistics) [7]. This suggests that it maybe informative to separately report the findings and adverse events on infants grouped as 32-33 weeks versus 34-36 weeks rather than combining these two groups in reporting morbidities such as hyperbilirubinemia.

Provider fear of hyperbilirubinemia has hindered the adoption of placental transfusion (DCC/UCM/C-UCM) throughout the world. Nevertheless, Zahir, et al. [8] suggested that bilirubin levels that are elevated but still within a normal range may provide a unique protective antioxidant effect, especially in the brain. We propose that more specific criteria for recognizing risk factors for hyperbilirubinemia be reported, including gestational age, G6PD, ABO incompatibility, and cephalhematoma. Use of the Bilitool (bilitool.org) may allow for quantification of risk. Although the Bilitool only includes infants 35 weeks and up, it could potentially be modified for research purposes to include infants 32 weeks through 34 weeks.

Another important issue from the study by Kumar,
et al. [4] is the use of “the cut by the obstetrician and milk by the neonatologist” technique. More research is needed to establish the benefits and/or potential harm of using C-UCM versus UCM or DCC. Recent animal studies suggest a smoother and better cardiorespiratory transition with DCC [9]. Yet, in some clinical situations DCC is not feasible. Combining DCC and UCM just prior to clamping may be beneficial in increasing ferritin levels over either method alone [10].

Kumar, et al. [4] confirm the importance of placental transfusion and its role in increasing ferritin levels in late preterm infants. However, the best method to accomplish this without increasing jaundice in late preterm infants is still unclear. Further long-term developmental follow-up in such studies may assist in deciphering the benefits from the risks.

Funding: None; Competing interests: The authors are principal investigators on an NIH funded trial “Effects of Placental Transfusion on Early Brain Development.”

REFERENCES